Recombinant Horse Cardiac troponin I/Tnni3 Protein，His & Myc

Cardiac troponin I (cTnI) is a crucial regulatory protein in cardiac muscle contraction, serving as a key biomarker for myocardial injury and heart diseases. Elevated levels of cTnI in the bloodstream are indicative of conditions such as acute myocardial infarction and heart failure, making it a vital target for diagnostic and therapeutic applications. The gene encoding this protein, Tnni3, is specifically expressed in cardiac tissues, differentiating it from its skeletal muscle counterpart. Research into the recombinant expression of cTnI has gained momentum due to its potential in improving diagnostic assays, understanding pathophysiological mechanisms of cardiac diseases, and developing novel therapeutic strategies. Recombinant cTnI enables the production of large quantities of pure protein, facilitating in-depth studies on its structure-function relationships. Such studies are essential for elucidating the molecular pathways involved in cardiac contractility and identifying potential interventions for heart disease. Additionally, the ability to manipulate the cTnI structure through recombinant technology may lead to innovative treatment options, such as targeted gene therapy or protein-based approaches to enhance cardiac function in pathological states. Understanding the properties of cTnI at a molecular level also has implications for the development of new biomarkers that can provide more accurate and timely diagnosis, thereby improving patient outcomes. Overall, the recombination and study of cardiac troponin I represent a significant frontier in cardiovascular research, promising enhanced diagnostic capabilities and therapeutic advancements in the field of cardiology.